Is durvalumab the solution for unresectable stage III non-small cell lung cancer?

被引：1
|
作者：
Duma, Narjust [1 ]
Mansfield, Aaron S. [1 ]
机构：
[1] Mayo Clin, Div Med Oncol, 200 First St SW, Rochester, MN 55905 USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2018年 / 7卷
关键词：
LIGAND; 1; EXPRESSION; PHASE-III; RADIOTHERAPY; CONCURRENT; TRIAL; IMMUNOTHERAPY; CISPLATIN; RADIATION; MEDI4736;
D O I：
10.21037/tcr.2018.01.16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S89 / S93
页数：5
相关论文
共 50 条
  • [1] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    [J]. JAMA NETWORK OPEN, 2024, 7 (04)
  • [2] Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer
    Shaverdian, Narek
    Offin, Michael D.
    Rimner, Andreas
    Shepherd, Annemarie F.
    Wu, Abraham J.
    Rudin, Charles M.
    Hellmann, Matthew D.
    Chaft, Jamie E.
    Gomez, Daniel R.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2020, 144 : 101 - 104
  • [3] Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice
    Furuhashi, K.
    Hataji, O.
    Nakamura, Y.
    Suzuki, Y.
    Sakaguchi, T.
    Ito, K.
    Fujiwara, K.
    Nishii, Y.
    Taguchi, O.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1104 - S1104
  • [4] Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
    Price, Katharine A. R.
    Azzoli, Christopher G.
    Gaspar, Laurie E.
    [J]. SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 204 - 209
  • [5] Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
    Tomasini, Pascale
    Greillier, Laurent
    Boyer, Arnaud
    Jeanson, Arnaud
    Barlesi, Fabrice
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S1032 - S1036
  • [6] Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era
    McCall, Neal S.
    McGinnis, Hamilton S.
    Janopaul-Naylor, James R.
    Kesarwala, Aparna H.
    Tian, Sibo
    Stokes, William A.
    Shelton, Joseph W.
    Steuer, Conor E.
    Carlisle, Jennifer W.
    Leal, Ticiana
    Ramalingam, Suresh S.
    Bradley, Jeffrey D.
    Higgins, Kristin A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2022, 174 : 133 - 140
  • [7] Impact of Radiation Dose to the Immune Cells in Unresectable or Stage III Non-Small Cell Lung Cancer in the Durvalumab Era
    Mccall, N. S.
    McGinnis, H. S.
    Janopaul-Naylor, J. R.
    Kesarwala, A. H.
    Tian, S.
    Stokes, W. A.
    Shelton, J. W.
    Steuer, C. E.
    Carlisle, J. W.
    Leal, T.
    Ramalingam, S. S.
    Bradley, J. D.
    Higgins, K. A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S109 - S109
  • [8] COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
    Herbst, R.
    Barlesi, F.
    Paz-Ares, L.
    Raben, D.
    Aggarwal, C.
    Bothos, J.
    Samadani, R.
    He, P.
    Angra, N.
    Martinez, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S450 - S451
  • [9] Optimal Treatment of Unresectable Stage III Non-Small Cell Lung Cancer
    Bradley, Jeffrey D.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 853 - 855
  • [10] PROGNOSTIC FACTORS IN UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER
    Boku, S.
    Kasamatsu, Y.
    Kida, T.
    Kasamatsu, Y.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
12345